摘要
目的观察氨甲环酸注射液联合丁二磺酸腺苷蛋氨酸注射剂用于肝癌手术患者的临床疗效及安全性。方法将63例拟进行肝癌手术的患者随机分为对照组30例和试验组33例。对照组于术前30 min予以丁二磺酸腺苷蛋氨酸1g,静脉注射;试验组于术前30 min予以丁二磺酸腺苷蛋氨酸1 g,静脉注射+氨甲环酸0. 75 g,静脉注射。比较2组患者的血清基质金属蛋白酶-2(MMP-2)、MMP-9和S100钙结合蛋白A4(S100A4)水平,以及药物不良反应的发生情况。结果术后24 h,试验组和对照组的MMP-2分别为(513. 56±52. 96)和(563. 74±60. 23) micrograms·L-1,MMP-9分别为(37. 75±2. 71)和(74. 94±5. 78) micrograms·L-1,S100A4分别为(52. 25±4. 95)和(73. 45±8. 44) ng·mL-1,差异均有统计学意义(均P <0. 05)。2组患者治疗期间均未发生明显的药物不良反应。结论氨甲环酸注射液联合丁二磺酸腺苷注射剂用于肝癌手术患者能有效地降低血清MMP-2、MMP-9和S100A4水平,且安全性较好。
Objective To observe the clinical efficacy and safety of tranexamic acid injection combined with ademetionine 1,4-butanedisulfonate injection in the treatment of patients with hepatocellular carcinoma surgery.Methods A total of 63 patients with liver cancer surgery were randomly divided into control group(n=30 cases)and treatment group(n=33 cases).30 min before operation,control group was given ademetionine 1,4-butanedisulfonate injection 1 g,intravenous injection.30 min before operation,treatment group was treated with ademetionine 1,4-butanedisulfonate injection as the control group,and tranexamic acid 0.75 g,intravenous injection.The serum levels of matrix metalloproteinase-2(MMP-2),MMP-9 and S100 calcium binding protein A4(S100A4),and adverse drug reactions were compared between two groups.Results 24 h after operation,the main indexes of treatment and control groups were compared:MMP-2 were(513.56±52.96)and(563.74±60.23)micrograms·L-1,MMP-9 were(37.75±2.71)and(74.94±5.78)micrograms·L-1,S100A4 were(52.25±4.95)and(73.45±8.44)ng·mL-1,and the differences were statistically significant(all P<0.05).There were no adverse drug reactions occurred during the treatment between two groups.Conclusion Tranexamic acid injection combined with ademetionine 1,4-butanedisulfonate injection can effectively reduce the serum levels of MMP-2,MMP-9 and S100A4,and the safety is high.
作者
林仙菊
王红珠
项海飞
LIN Xian-ju;WANG Hong-zhu;XIANG Hai-fei(Department of Surgery,Enze Hospital,Taizhou Enze Medical Center(Group),Taizhou 318053,Zhejiang Province,China;Department of Surgery,Taizhou Hospital,Taizhou Enze Medical Center(Group),Taizhou 317000,Zhejiang Province,China)
出处
《中国临床药理学杂志》
CAS
CSCD
北大核心
2019年第11期1116-1118,共3页
The Chinese Journal of Clinical Pharmacology
基金
浙江省医药卫生科技计划课题资助项目(2012KYB233)
关键词
氨甲环酸注射液
丁二磺酸腺苷蛋氨酸
肝癌
安全性评价
tranexamic acid injection
ademetionine 1,4-butanedisulfonate injection
liver cancer
safety evaluation